Search research articles
Contact Us
Filters
Showing results (331-340 of 404) with videos related to
Page
of 41
Sort By:
Clinical & Experimental Metastasis
|
September 6, 2025
Prognostic immunotherapy score (PIS) in patients with advanced urothelial carcinoma treated with pembrolizumab: real-world data and validation from ARON-2 dataset
Alessandro Rizzo, Anas Zayed, Elsa Vitale, et al.
Expert Review of Anticancer Therapy
|
April 5, 2023
Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome?
Matilde Corianò, Diana Giannarelli, Giulia Scartabellati, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 23, 2013
Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort
Roberto Iacovelli, Giacomo Cartenì, Cora N Sternberg, et al.
Frontiers in Bioscience (Elite Edition)
|
September 24, 2023
Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score
Giulia Mazzaschi, Alessandro Lazzarin, Matteo Santoni, et al.
European Urology Oncology
|
June 4, 2026
Doublet Versus Triplet Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer Patients with Bone Metastases: Results from the ARON-3 Study
Philipp Cornelius Mandel, Mike Wenzel, María Natalia Gandur Quiroga, et al.
European Urology Oncology
|
April 4, 2024
Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study
Francesco Massari, Veronica Mollica, Ondrej Fiala, et al.
Oncotarget
|
March 31, 2016
Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma
Daniele Santini, Matteo Santoni, Alessandro Conti, et al.
Cancer Immunology, Immunotherapy : CII
|
January 3, 2025
First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study
Giandomenico Roviello, Javier Molina-Cerrillo, Francesco Massari, et al.
BMC Cancer
|
May 1, 2026
Enfortumab vedotin in ECOG-PS 2 advanced urothelial carcinoma patients: a real-world study from the ARON-2<sup>EV</sup> project
Alessandro Rizzo, Francesco Ciccimarra, Stenio de Casio Zequi, et al.
Clinical Genitourinary Cancer
|
August 1, 2020
Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study
Maria Giuseppa Vitale, Stefania Pipitone, Marta Venturelli, et al.
Page
of 41
Search research articles
Search
Showing results (331-340 of 404) with videos related to
Sort By:
Page
of 41
Clinical & Experimental Metastasis
|
September 6, 2025
Prognostic immunotherapy score (PIS) in patients with advanced urothelial carcinoma treated with pembrolizumab: real-world data and validation from ARON-2 dataset
Alessandro Rizzo, Anas Zayed, Elsa Vitale, et al.
Expert Review of Anticancer Therapy
|
April 5, 2023
Tailoring treatment with cabozantinib or pazopanib in patients with metastatic renal cell carcinoma: does it affect outcome?
Matilde Corianò, Diana Giannarelli, Giulia Scartabellati, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 23, 2013
Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort
Roberto Iacovelli, Giacomo Cartenì, Cora N Sternberg, et al.
Frontiers in Bioscience (Elite Edition)
|
September 24, 2023
Integrating Red Blood Cell Features and Hemoglobin Levels in Metastatic Renal Cell Carcinoma Patients Treated with Pazopanib or Cabozantinib: An Easily Exploitable Prognostic Score
Giulia Mazzaschi, Alessandro Lazzarin, Matteo Santoni, et al.
European Urology Oncology
|
June 4, 2026
Doublet Versus Triplet Therapy in High-volume Metastatic Hormone-sensitive Prostate Cancer Patients with Bone Metastases: Results from the ARON-3 Study
Philipp Cornelius Mandel, Mike Wenzel, María Natalia Gandur Quiroga, et al.
European Urology Oncology
|
April 4, 2024
Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study
Francesco Massari, Veronica Mollica, Ondrej Fiala, et al.
Oncotarget
|
March 31, 2016
Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma
Daniele Santini, Matteo Santoni, Alessandro Conti, et al.
Cancer Immunology, Immunotherapy : CII
|
January 3, 2025
First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study
Giandomenico Roviello, Javier Molina-Cerrillo, Francesco Massari, et al.
BMC Cancer
|
May 1, 2026
Enfortumab vedotin in ECOG-PS 2 advanced urothelial carcinoma patients: a real-world study from the ARON-2<sup>EV</sup> project
Alessandro Rizzo, Francesco Ciccimarra, Stenio de Casio Zequi, et al.
Clinical Genitourinary Cancer
|
August 1, 2020
Correlation Between Immune-related Adverse Event (IRAE) Occurrence and Clinical Outcome in Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Nivolumab: IRAENE Trial, an Italian Multi-institutional Retrospective Study
Maria Giuseppa Vitale, Stefania Pipitone, Marta Venturelli, et al.
Page
of 41